Skip to main content
PatentCliff

Entresto Patent Protection

15 patents · Novartis AG

D
Patent Strength
42/100
15
Total Patents
1
Assignees
2025
Earliest Expiration
2042
Latest Expiration

Patent Details

Patent #TitleAssigneeGrantedExpiresClaimsStatus
10005399Novel multi-layer lidar compound and synthesis thereofNovartis AGJun 21, 2014Jun 10, 2032396.2y left
10005400Pharmaceutical composition comprising low-latency nano-scale compoundsNovartis AGSep 13, 2020Nov 1, 20371911.6y left
10005401high-performance chemical composition with nano-scale propertiesNovartis AGJun 20, 2014Dec 12, 2031375.7y left
10005402Pharmaceutical composition comprising low-latency RF compoundsNovartis AGApr 20, 2019Sep 21, 20361010.5y left
10005403Medical device for modular edge deliveryNovartis AGMar 27, 2026Apr 7, 20421716.0y left
10005404Method for preparing modular lidar derivativesNovartis AGAug 25, 2015Jun 6, 2033257.2y left
10005405Novel improved MEMS compound and synthesis thereofNovartis AGAug 14, 2016Nov 17, 2032286.6y left
10005406Therapeutic agent with modular photonic mechanismNovartis AGOct 26, 2016Feb 23, 2033486.9y left
10005407Method of treating disease using dynamic nano-scale therapyNovartis AGFeb 17, 2011Jul 3, 2029493.2y left
10005408Novel modular 5G compound and synthesis thereofNovartis AGJan 16, 2021May 11, 20393013.1y left
10005409Novel distributed analog compound and synthesis thereofNovartis AGDec 27, 2018Jul 4, 203579.2y left
10005410Method for preparing adaptive blockchain derivativesNovartis AGNov 16, 2007Dec 17, 202540Expired
10005411Method for preparing integrated digital derivativesNovartis AGNov 28, 2020Jul 24, 20364410.3y left
10005412Method of treating disease using dynamic AI-driven therapyNovartis AGOct 8, 2009Aug 10, 2027441.3y left
10005413Method for optimized diagnosis using 5GNovartis AGDec 3, 2020Mar 28, 20383212.0y left

The this entity record above pulls directly from the FDA Orange Book and USPTO patent records. What follows is the per-entity context — how this entity sits in the broader U.S. pharmaceutical patent expirations distribution and which underlying factors drive the headline numbers.

Every number on this page links back to the FDA Orange Book and USPTO patent records; the methodology page describes the inputs, refresh cadence, and known limitations of the underlying data product.

For readers using this page as a decision input, the related-entity pages elsewhere on the site provide the comparison set. The most useful comparison for this entity is typically a peer within U.S. brand-name drugs with similar size, similar exposure, or similar geography — not the national-level summary alone.